K050465 · Immunalysis Corporation · DIO · Aug 4, 2005 · Clinical Toxicology
Device Facts
Record ID
K050465
Device Name
IMMUNALYSIS COCAINE ELISA FOR HAIR
Applicant
Immunalysis Corporation
Product Code
DIO · Clinical Toxicology
Decision Date
Aug 4, 2005
Decision
SESE
Submission Type
Traditional
Regulation
21 CFR 862.3250
Device Class
Class 2
Indications for Use
The Immunalysis Cocaine ELISA Kit for Hair test system utilizes an Enzyme Linked Immunoassay (ELISA) for the qualitative detection of cocaine in head hair samples using a cutoff of 500 pg/mg (0.5 ng/mg) of hair for the purpose of identifying chronic cocaine use. This process has not been evaluated for use with hair specimens other than head. This in vitro diagnostic device is intended for clinical laboratory use only. The Immunalysis Cocaine ELISA Kit for Hair test system provides only a preliminary analytical test result. For confirmation of the results, presumptive positives are analyzed using a gas chromatograph - mass spectrometer operating in electron impact mode and using deuterated internal standards. Clinical and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are obtained. This device is for prescription use only.
Device Story
Immunalysis Cocaine ELISA Kit for Hair is an in vitro diagnostic test for identifying chronic cocaine use. Input: head hair samples. Principle: Enzyme Linked Immunoassay (ELISA) targeting cocaine metabolites. Output: qualitative preliminary analytical result based on 500 pg/mg cutoff. Context: clinical laboratory setting; performed by laboratory personnel. Presumptive positive results require confirmation via gas chromatography-mass spectrometry (GC-MS) using deuterated internal standards. Clinical judgment required for interpretation. Benefits: provides screening tool for chronic cocaine exposure.
Clinical Evidence
No clinical data provided. Device evaluation based on analytical performance characteristics typical of in vitro diagnostic ELISA test systems.
Technological Characteristics
Solid-phase microtiter plate ELISA; polyclonal sheep anti-cocaine antibodies. Extraction: aqueous (phosphate buffer) or methanolic (methanol/acetic acid). Detection: colorimetric (450/620 nm). Confirmation: GC-MS (electron impact mode). Form factor: 96-well plate. No specific ASTM standards cited.
Indications for Use
Indicated for qualitative detection of cocaine in head hair samples to identify chronic cocaine use. Intended for clinical laboratory use. Not evaluated for non-head hair specimens. Requires confirmatory testing via GC-MS for presumptive positives.
Regulatory Classification
Identification
A cocaine and cocaine metabolite test system is a device intended to measure cocaine and a cocaine metabolite (benzoylecgonine) in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of cocaine use or overdose.
Special Controls
*Classification.* Class II (special controls). A cocaine and cocaine metabolite test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
Submission Summary (Full Text)
{0}
# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE ONLY TEMPLATE
A. 510(k) Number:
k050465
B. Purpose for Submission:
New Device
C. Measurand:
Cocaine
D. Type of Test:
Qualitative immunoassay
E. Applicant:
Immunalysis Corporation
F. Proprietary and Established Names:
Immunalysis Cocaine ELISA Kit for Hair
G. Regulatory Information:
1. Regulation section:
21 CFR § 862.3250
Enzyme Immunoassay, Cocaine and Cocaine Metabolites
2. Classification:
Class II
3. Product Code:
DIO
4. Panel:
Toxicology (91)
H. Intended Use:
1. Intended use(s):
Refer to Indications for use.
2. Indication(s) for use:
The Immunalysis Cocaine ELISA Kit for Hair test system utilizes an Enzyme Linked Immunoassay (ELISA) for the qualitative detection of cocaine in head hair samples using a cutoff of 500 pg/mg (0.5 ng/mg) of hair for the purpose of identifying chronic cocaine use. This process has not been evaluated for
{1}
Page 2 of 15
use with hair specimens other than head. This in vitro diagnostic device is intended for clinical laboratory use only.
The Immunalysis Cocaine ELISA Kit for Hair test system provides only a preliminary analytical test result. For confirmation of the results, presumptive positives are analyzed using a gas chromatograph - mass spectrometer operating in electron impact mode and using deuterated internal standards. Clinical and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are obtained.
This device is for prescription use only.
Characterization of the performance of the device was limited to two distinct study populations; individuals who were self-reported to be cocaine users and individuals who were self-reported to be non-users.
3. Special condition for use statement(s):
The Immunalysis Cocaine ELISA Kit for Hair combines a screening method (ELISA) with a confirmation method (GC-MS) in one test system. A negative screening result is reported as negative. A presumptive positive screening result is not reported until it has been confirmed by GC-MS.
The assay is not designated for use in point-of-care settings.
4. Special instrument Requirements:
See device description below.
I. Device Description:
The Immunalysis Cocaine ELISA Kit for Hair is a complete system for detecting cocaine in hair using a combination of an immunoassay and a GC-MS confirmation procedure. The screening assay uses a standard 96 well microtiter plate and reader. Confirmation testing is done by GC-MS operating in electron impact mode using deuterated internal standards.
J. Substantial Equivalence Information:
1. Predicate device name(s): DRI Cocaine Metabolite EIA
2. Predicate K number(s): k960187
3. Comparison with predicate
{2}
Page 3 of 15
| Similarities | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Analyte | Same | Cocaine |
| Methodology | Same (for screening test) | Immunoassay |
| Differences | | |
| Item | Device | Predicate |
| Antibody | Polyclonal anti-cocaine | Monoclonal anti-benzoylecgonine |
| Instrumentation | Microplate Reader | Automated Clinical Chemistry Analyzers |
| Matrix | Hair (Cutoff 500 pg/mg) | Urine (Cutoff 300 ng/mL) |
K. Standard/Guidance Document Referenced (if applicable):
The sponsor did not reference any standards in their submission.
L. Test Principle:
The Immunalysis Cocaine ELISA Kit for Hair is a complete system for detecting cocaine in hair using the combination of an immunoassay and a GC-MS confirmation procedure. The screening assay is a solid-phase microtiter plate ELISA. The test is performed in microwells coated with polyclonal antibodies of sheep origin to cocaine. Hair samples are collected as close to the scalp as possible and preferably from the back of the head near the crown. The sponsor states that 100 hair strands with a length of 4 cm will give approximately 100 mg of hair. The 4 cm lengths are then cut into smaller segments of 3-5 mm, mixed to ensure homogeneity, and weighed into 10 mg aliquots. Prior to extraction, the hair is washed briefly with methanol, the solvent is decanted, and the hair is allowed to dry.
The sponsor has included two distinct extraction steps in their labeling. Users may choose one or the other depending on their needs. For the aqueous extraction, 0.5 mL of a 0.025 M monobasic phosphate buffer is added to the hair samples, the tubes are capped and incubated at 60 °C for one hour. 0.5 M dibasic phosphate buffer is added to neutralize the acid environment and the liquids are transferred to corresponding clean glass tubes. All specimens, calibrators and controls are then diluted 1:5 by adding 400 uL of phosphate buffer saline (100 mM PBS with 0.1% BSA, pH 7.0) to 100 uL of hair extract. For the methanolic extraction, 2 mL of Methanol with 1% v/v of Glacial Acetic Acid is added to the hair samples, the tubes are capped and incubated at 60 °C for one hour. After an hour the methanol is transferred to clean tubes and evaporated under nitrogen. The tubes are then reconstituted with 550 uL of 100 mM Phosphate buffered Saline pH 7.0 containing 0.1% BSA. All specimens, calibrators and controls are then diluted 1:5 by adding 400 uL of phosphate buffer saline (PBS with 0.1% BSA, pH 7.0) to 100 uL of the reconstituted hair extract.
To begin the ELISA procedure, 20 µL aliquots of controls, calibrators, and patient samples are added to the sample well, followed by the Enzyme Conjugate. During
{3}
Page 4 of 15
the 60 minute incubation that follows, the enzyme conjugate competes with the analyte in the samples for binding sites on the antibody-coated microwells. After the incubation the wells are washed six times with DI water to remove any unbound materials such as excess conjugate or residual sample. Enzyme substrate is then added to each well and incubated for 30 minutes at room temperature, preferably in the dark. At 30 minutes the stop solution is added to each well, which changes the color from blue to yellow. The absorbance of each well is read at 450 and 620 nm and users are instructed to read the plates within 30 minutes of yellow color development. If the average sample absorbance is greater than the average absorbance of the cutoff calibrator of 500 pg/mg, the sample is interpreted as NEGATIVE for Cocaine at 500 pg/mg of hair. A negative interpretation means that the sample does not contain cocaine or cocaine is present at a concentration below the cutoff level for this assay. If the average sample absorbance is equal to or less than the average absorbance of the laboratory cutoff calibrator of 500 pg/mg, the sample is interpreted as presumptive POSITIVE for Cocaine at 500 pg/mg of hair. A presumptive positive interpretation means that the sample contains cocaine at a concentration at or above the cutoff concentration.
Other structurally similar compounds can produce positive results. Compounds that are not structurally similar to cocaine have not been observed to produce positive results, however false positive screening results may occur because of non-specific binding or other technical problems.
Presumptive positives are carried forward to the confirmation procedure utilizing GC-MS. A 20 mg aliquot of hair from the original hair specimen is weighed out and incubated with methanol at room temperature for 1-5 minutes, after which the methanol is discarded. Deuterated internal standards are added to each calibrator, control, or unknown tube followed by a two hour incubation with hydrochloric acid at 75 °C. After the incubation the acid is decanted into clean glass tubes, 0.1 M phosphate buffer is added, and the pH is adjusted with 0.1 M sodium hydroxide. Solid phase extraction columns are conditioned with a mixture of methylene chloride, isopropanol, ammonium hydroxide, methanol, and phosphate buffer, after which the samples are allowed to flow through the columns with no vacuum. After washing with deionized water, hydrochloric acid, and methanol, the columns are dried at high pressure for five minutes. The drug is then eluted into collection tubes with a mixture of fresh methylene chloride, isopropanol, and ammonium hydroxide, and the extracts are evaporated to dryness. The extracts are then derivatized with pentafluoropropanol and pentafluoropropionic anhydride, evaporated to dryness, and reconstituted with pyridine/ethyl acetate prior to transfer into auto-sampling vials for GC-MS analysis.
Interpretation of Confirmatory Testing Results: Samples are considered positive for cocaine use if*:
- Cocaine is present at or above 500 pg/mg AND the benzoylecgonine / cocaine ratio is ≥ 0.05
OR
{4}
Page 5 of 15
- Norcocaine is present at or above 50 pg/mg
OR
- Cocaethylene is present at or above 50 pg/mg
* SAMHSA proposed guidelines April 13, 2004
Interpretation of results must take into account that drug concentrations detected in hair from a single individual can vary extensively depending on the site of collection. Positive screening results only indicate the presumptive presence of cocaine, and require additional analysis by mass spectrometry to obtain a confirmed result. A negative screening result does not necessarily rule out the possibility of cocaine use, i.e., time of collection, frequency of use, mode of ingestion, dosage used, hair types and other factors may influence results. It is not possible to document all possible effects due to treatments such as bleaching, straightening and dying. There is a possibility that other substances and/or factors that were not evaluated in the interference studies may interfere with the test and cause false results that cannot be confirmed by mass spectrometry, e.g. technical or procedural errors.
## M. Performance Characteristics (if/when applicable):
### 1. Analytical performance:
#### a. Precision/Reproducibility:
**Within-Run Precision Using Spiked (Contrived) Samples**
The intra-assay analytical precision of the screening assay was evaluated by analyzing sixteen replicate samples at five different concentrations in one run. To prepare the samples, a pool of previously washed certified negative hair was spiked with cocaine in methanol at concentrations of 250, 500, 750, and 1000 pg/mg of cocaine, which correspond to 50%, 100%, 150%, and 200%, respectively of the sponsor's recommended cutoff concentration. A zero concentration sample was also included in the experiment. The study used one lot of reagent and was performed by two of the sponsor's employees at the sponsor's quality control laboratory. The results are summarized as follows:
| Spiked Concentration (pg/mg) | Mean Optical Density | Standard Deviation | % Coefficient of Variation | Lower 95% Confidence Interval | Upper 95% Confidence Interval of Mean Optical Density |
| --- | --- | --- | --- | --- | --- |
| 0 | 2.991 | 0.037 | 1.25 | 2.971 | 3.012 |
| 250 | 2.016 | 0.083 | 4.13 | 1.97 | 2.062 |
| 500 | 1.558 | 0.047 | 3.04 | 1.531 | 1.584 |
| 750 | 1.442 | 0.049 | 3.40 | 1.415 | 1.469 |
| 1000 | 1.223 | 0.041 | 3.39 | 1.201 | 1.246 |
{5}
Page 6 of 15
## Between-Run Precision Using Spiked (Contrived) Samples
The between-run analytical precision of the screening assay was similarly evaluated by analyzing four different concentrations in eight runs over three days. The preparation of the samples was the same as for Within-Run Precision above, and the concentrations used were 0, 250, 500, 750, and 1000 pg/mg. The study used two lots of reagents and was performed by two of the sponsor's employees at the sponsor's Quality Control laboratory. The results are summarized as follows:
| Spiked Concentration (pg/mg) | Mean Optical Density | Standard Deviation | % Coefficient of Variation | Lower 95% Confidence Interval | Upper 95% Confidence Interval of Mean Optical Density |
| --- | --- | --- | --- | --- | --- |
| 0 | 3.209 | 0.062 | 1.94 | 3.157 | 3.261 |
| 250 | 2.152 | 0.136 | 6.30 | 2.038 | 2.266 |
| 500 | 1.688 | 0.098 | 5.81 | 1.606 | 1.770 |
| 750 | 1.472 | 0.071 | 4.84 | 1.413 | 1.514 |
| 1000 | 1.318 | 0.065 | 4.92 | 1.264 | 1.372 |
## Between-Run Precision Using Previously Analyzed Positive Hair Samples
The between-run analytical precision of the screening assay was also evaluated using hair specimens which had previously been assayed and had produced readings between the low control (250 pg/mg) and high control (1000 pg/mg). These specimens span a range of colors including black, gray, brown and blond. Since the sponsor's procedure includes the option of either an aqueous or methanolic extraction, both were evaluated. Five replicates of four previously positive samples were assayed using the aqueous extraction, and five replicates of five previously positive samples were assayed using the methanolic extraction. The results are summarized as follows:
### Aqueous Extraction
| Sample # | DT0086 | DT0112 | DT0147 | DT0110 |
| --- | --- | --- | --- | --- |
| Replicate 1 OD | 1.152 | 1.344 | 1.352 | 0.883 |
| Replicate 2 OD | 1.288 | 1.301 | 1.287 | 0.995 |
| Replicate 3 OD | 1.199 | 1.180 | 1.309 | 0.926 |
| Replicate 4 OD | 1.356 | 1.306 | 1.351 | 0.819 |
| Replicate 5 OD | 1.409 | 1.388 | 1.333 | 0.975 |
| Mean | 1.281 | 1.304 | 1.326 | 0.910 |
| Standard Deviation | 0.107 | 0.078 | 0.028 | 0.080 |
| % Coefficient of Variation | 8.33 | 5.95 | 2.12 | 8.85 |
{6}
Page 7 of 15
| Controls and Calibrators for Aqueous Extraction | Zero | Low Control | Calibrator | High Control |
| --- | --- | --- | --- | --- |
| Optical Density | 2.553 | 1.672 | 1.294 | 0.948 |
## Methanolic Extraction
| Sample # | DT0002 | DT0011 | DT0079 | DT0108 | DT 0290 |
| --- | --- | --- | --- | --- | --- |
| Replicate 1 OD | 1.331 | 1.008 | 1.115 | 1.009 | 1.509 |
| Replicate 2 OD | 1.296 | 0.942 | 1.342 | 0.882 | 1.382 |
| Replicate 3 OD | 1.402 | 0.999 | 1.255 | 0.941 | 1.241 |
| Replicate 4 OD | 1.257 | 1.102 | 1.199 | 0.962 | 1.366 |
| Replicate 5 OD | 1.508 | 1.255 | 1.203 | 0.951 | 1.392 |
| Mean | 1.359 | 1.055 | 1.223 | 0.949 | 1.378 |
| Standard Deviation | 0.099 | 0.111 | 0.083 | 0.046 | 0.095 |
| % Coefficient of Variation | 7.29 | 10.51 | 6.82 | 4.81 | 6.91 |
| Controls and Calibrators for Methanolic Extraction | Zero | Low Control | Calibrator | High Control |
| --- | --- | --- | --- | --- |
| Optical Density | 2.422 | 1.622 | 1.278 | 0.933 |
b. Linearity/assay reportable range:
Not applicable. The assay is intended for qualitative use.
c. Traceability (controls, calibrators, or method):
Calibrators and controls are required but not supplied. The sponsor has included instructions in their labeling for preparing calibrators and controls from commercially available stock cocaine solutions.
d. Detection limit:
{7}
Page 8 of 15
The analytical sensitivity was estimated by measuring the absorbance of negative hair samples, and spiked samples at 15, 30, 60, 125, 250, and 500 pg/mg. The means and standard deviations were calculated. The concentration corresponding to the mean minus two standard deviations was calculated to be approximately 12 pg/mg. The sponsor has chosen to use the more conservative figure of 15 pg/mg in their labeling.
e. Analytical specificity:
Cross-Reactivity with structurally unrelated compounds: To assess the potential for positive and/or negative interference the sponsor prepared negative hair matrix, negative hair matrix spiked at the cutoff minus 50%, and negative hair matrix spiked at the cutoff plus 50%. The sponsor then spiked the equivalent of 500,000 pg/mg of the following compounds into the prepared matrices. There was no deviation from the expected results; i.e., the negative samples all had an immunoassay response below the detection limit of the assay, the samples at the cutoff minus 50% read negative, and the samples at the cutoff plus 50% read positive.
Acetaminophen, Acetylsalicylic acid, Amphetamine, Aminopyrine, Amitryptyline, Ampicillin, Amobarbital, Ascorbic acid, Atropine, Barbital, Butabarbital, Bromazepam, Caffeine, Carbamazepine, Codeine, Chloroquine, Chlorpheniramine, Chlorpromazine, Carbromal, Desipramine, Dextromethorphan, Dextropropoxyphene, Diacetylmorphine, 5,5Diphenylhydantoin, 10-1 11 - Dihydrocarbamazepine, Diazepam, Doxepin, Doxylamine, Ethosuximide, Ethotoin, Flurazepam, Glutethimide, Hexobarbital, Hydrocodone, Hydromorphone, Ibuprofen, Imipramine, Lidocaine, Lorazepam, LSD, Medazepam, Methadone, Methadone - primary metabolite, Methaqualone, Methamphetamine, Metharbital, Mephenytoin, Methylphenidate, Methyl-propylsuccinimide, Mephobarbital, Methyl PEMA, Methsuximide, 4-Methylprimidone, Morphine, Meperidine, Nalorphine, Niacinamide, Nordoxepin, Norethindrone, N-Normethsuximide, Nortriptyline, Oxazepam, Oxycodone, PEMA, Pentobarbital, Phencyclidine, Pheniramine, Phenobarbital, Phensuximide, Phenothiazine, Phenylpropanolamine, Primidone, Procaine, Promethazine, Protriptyline, Quinine, Secobarbital, Temazepam, Tetracycline, Tetrahydrozoline, THCCOOH, Trimipramine
Cross-Reactivity with structurally similar compounds: To assess cross-reactivity, serial dilutions were prepared in negative hair matrix for each of the compounds listed in the table below. The concentration of compound that produced absorbance readings
{8}
Page 9 of 15
similar to the cutoff calibrator was recorded and from this a percent cross-reactivity was calculated
| Structurally Similar Compound | Concentration equivalent to 500 pg/mg (cutoff concentration) | Percent Cross-Reactivity |
| --- | --- | --- |
| Cocaine | 500 pg/mg | 100 |
| Benzoylecgonine | 5500 pg/mg | 9 |
| Cocaethylene | 375 pg/mg | 133 |
| m-hydroxybenzoylecgonine | 9000 pg/mg | 5.5 |
| Benzoylecgonine Isopropyl Ester | 250 pg/mg | 200 |
| Norcocaine | 10,000 pg/mg | 5 |
| Norbenzoylecgonine | 20,000 pg/mg | 2.5 |
| Norcocaethylene | 9000 pg/mg | 5.5 |
| Ecgonine | >50,000 pg/mg | <1 |
| Ecgonine Methyl Ester | >50,000 pg/mg | <1 |
There is the possibility that other substances and/or factors not listed above may interfere with the test and cause false results, e.g., technical or procedural errors.
f. Assay cut-off:
Characterization of how the device performs analytically around the claimed cutoff concentration appears in the precision section, above.
g. Environmental Contamination Study
To assess the influence of environmental contamination on the assay, the sponsor performed the following experiment. Cocaine was added to an artificially synthesized sweat solution, and samples of drug-free hair were incubated in this solution. The sponsor studied the variables of hair color, cocaine concentration, length of incubation, and washing. Results were as follows:
| Hair Color | Concentration of Soaking Solution (ng/mL) | Incubation Time (hrs) | Wash with Methanol | ELISA result | GC-MS Confirmation Result |
| --- | --- | --- | --- | --- | --- |
| Light | 100 | 4 | Yes | + | + |
| Light | 100 | 4 | No | + | + |
| Black | 100 | 4 | Yes | - | - |
| Black | 100 | 4 | No | - | - |
| Light | 10 | 4 | Yes | - | - |
| Light | 10 | 4 | No | - | - |
{9}
Page 1
| Hair Color | Concentration of Soaking Solution (ng/mL) | Incubation Time (hrs) | Wash with Methanol | ELISA result | GC-MS Confirmation Result |
| --- | --- | --- | --- | --- | --- |
| Black | 10 | 4 | Yes | - | - |
| Black | 10 | 4 | No | - | - |
| Light | 100 | Overnight* | Yes | - | - |
| Light | 100 | Overnight | No | + | - |
| Black | 100 | Overnight | Yes | - | + |
| Black | 100 | Overnight | No | - | + |
| Light | 10 | Overnight | Yes | - | - |
| Light | 10 | Overnight | No | - | - |
| Black | 10 | Overnight | Yes | - | - |
| Black | 10 | Overnight | No | - | - |
*exact time not specified
Of the eight samples that were soaked in a 10 ng/mL solution, none tested positive by the ELISA assay or GC-MS. Of the eight samples that were soaked in a 100 ng/mL solution, five were positive by ELISA and/or GC-MS.
h. Stability Study
The sponsor obtained from a reference laboratory 41 hair samples which had previously been confirmed positive by GC-MS at a cutoff of 500 pg/mg cocaine. The samples were stored at room temperature for 12-14 months, re-extracted by the aqueous and/or methanolic methods, and analyzed by the sponsor’s ELISA method. If enough hair was available the samples were also re-analyzed by GC-MS.
{10}
Page 11
| Aqueous Extraction | Prior to storage | | | | After Storage | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Hair color | cocaine | BZE | norcocaine | cocaethylene | Immunolysis ELISA | cocaine | BZE | norcocaine | cocaethylene |
| BLACK | 8906 | 2578 | 0 | 0 | + | 6310 | 2440 | 0 | 0 |
| BROWN | 1276 | 3006 | 0 | 0 | + | 1040 | 2890 | 0 | 0 |
| BROWN | 731 | 70 | 0 | 0 | + | 690 | 65 | 0 | 0 |
| BLACK | 4843 | 581 | 0 | 0 | + | 4610 | 520 | 0 | 0 |
| BLACK | 1490 | 169 | 0 | 0 | + | 1130 | 140 | 0 | 0 |
| BLACK | 4281 | 199 | 0 | 0 | + | 3150 | 174 | 0 | 0 |
| BLACK | 1634 | 99 | 0 | 0 | - | 1510 | 110 | 0 | 0 |
| GREY | 10811 | 472 | 0 | 0 | + | 9955 | 635 | 0 | 0 |
| BROWN | 3149 | 172 | 75 | 0 | + | 2810 | 195 | 61 | 0 |
| BLACK | 3120 | 410 | 0 | 0 | + | 2530 | 390 | 0 | 0 |
| BLACK | 14530 | 1040 | 0 | 0 | + | 9980 | 995 | 0 | 0 |
| BLONDE | 4843 | 477 | 0 | 0 | + | 4340 | 559 | 0 | 0 |
| BROWN | 540 | 150 | 0 | 0 | + | 530 | 126 | 0 | 0 |
| BLACK | 22960 | 1710 | 0 | 3390 | + | 19880 | 1630 | 0 | 3170 |
| BLACK | 11310 | 960 | 0 | 220 | + | 10540 | 1050 | 0 | 185 |
| DK BRN | 13710 | 960 | 0 | 1700 | + | 12980 | 880 | 0 | 1495 |
| BLACK | 6860 | 1850 | 0 | 0 | + | 6340 | 2010 | 0 | 0 |
| DK BRN | 7480 | 810 | 0 | 0 | + | 7190 | 960 | 0 | 0 |
| BLACK | 580 | Not Performed | Not Performed | Not Performed | + | Insufficient Sample For GC-MS Analysis | | | |
| GREY | 4450 | Not Performed | Not Performed | Not Performed | + | | | | |
| BLACK | 1990 | Not Performed | Not Performed | Not Performed | + | | | | |
| BLACK | 9130 | Not Performed | Not Performed | Not Performed | + | | | | |
| BLACK | 2000 | Not Performed | Not Performed | Not Performed | + | | | | |
| BLACK | 4210 | Not Performed | Not Performed | Not Performed | + | 3350 | 730 | 0 | 115 |
| BLACK | 1400 | Not Performed | Not Performed | Not Performed | + | 1310 | 240 | 0 | 0 |
| BLACK | 4200 | Not Performed | Not Performed | Not Performed | + | 4090 | 310 | 95 | 0 |
| BLACK | 1790 | Not Performed | Not Performed | Not Performed | + | 1450 | 159 | 0 | 65 |
| BLACK | 4924 | 0 | 143 | 0 | - | 3370 | 195 | 120 | 0 |
| BROWN | 16185 | 0 | 512 | 0 | + | 15600 | 126 | 390 | 0 |
| BLACK | 19088 | 0 | 453 | 0 | + | 17200 | 225 | 425 | 0 |
| BLACK | 13074 | 0 | 0 | 0 | + | 10900 | 740 | 0 | 0 |
| BLACK | 271071 | 27281 | 0 | 0 | + | 223500 | 31500 | 0 | 0 |
| BLACK | 2767 | 363 | 41 | 152 | + | 2350 | 426 | 65 | 99 |
| BLACK | 24211 | 2082 | 0 | 9599 | + | 22100 | 1850 | 0 | 8875 |
| BLACK | 3875 | 299 | 2237 | 15.6 | + | 3670 | 245 | 2100 | 0 |
| BLACK | 23850 | 2563 | 1035 | 5031 | + | 19700 | 2375 | 990 | 4750 |
| BLONDE | 2539 | 289 | 36 | 0 | + | 2200 | 207 | 0 | 0 |
| BLONDE | 3478 | 226 | 0 | 0 | + | 3180 | 269 | 0 | 0 |
| BLACK | 299654 | 48105 | 17289 | 3398 | + | 260500 | 56700 | 16850 | 2840 |
| BLACK | 25943 | 2971 | 834 | 7814 | + | 23700 | 3590 | 935 | 7680 |
| GREY | 10330 | 746 | 285 | 2372 | + | 9950 | 880 | 250 | 2250 |
{11}
Using the aqueous extraction method, two out of the 41 previously positive samples produced negative results after storage at room temperature. Both samples contained cocaine but at levels below the cutoff of the ELISA assay.
| Methanolic Extraction | Prior to storage | | | | After Storage | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| COLOR | COC | BE | NORCOC | COCAETH | ELISA | COC | BE | NORCOC | COCAETH |
| BLACK | 8906 | 2578 | 0 | 0 | + | 6310 | 2440 | 0 | 0 |
| BROWN | 1276 | 3006 | 0 | 0 | + | 1040 | 2890 | 0 | 0 |
| BROWN | 731 | 70 | 0 | 0 | + | 690 | 65 | 0 | 0 |
| BLACK | 4843 | 581 | 0 | 0 | + | 4610 | 520 | 0 | 0 |
| BLACK | 1490 | 169 | 0 | 0 | + | 1130 | 140 | 0 | 0 |
| BLACK | 4281 | 199 | 0 | 0 | + | 3150 | 174 | 0 | 0 |
| BLACK | 1634 | 99 | 0 | 0 | - | 1510 | 110 | 0 | 0 |
| GREY | 10811 | 472 | 0 | 0 | + | 9955 | 635 | 0 | 0 |
| BLACK | 3120 | 410 | 0 | 0 | + | 2530 | 390 | 0 | 0 |
| BLACK | 14530 | 1040 | 0 | 0 | + | 9980 | 995 | 0 | 0 |
| BLONDE | 4843 | 477 | 0 | 0 | + | 4340 | 559 | 0 | 0 |
| BLACK | 22960 | 1710 | 0 | 3390 | + | 19880 | 1630 | 0 | 3170 |
| DK BRN | 7480 | 810 | 0 | 0 | + | 7190 | 960 | 0 | 0 |
| BLACK | 580 | Not Performed | Not Performed | Not Performed | + | Insufficient Sample For GC-MS Analysis | | | |
| GREY | 4450 | Not Performed | Not Performed | Not Performed | + | | | | |
| BLACK | 1990 | Not Performed | Not Performed | Not Performed | + | | | | |
| BLACK | 9130 | Not Performed | Not Performed | Not Performed | + | | | | |
| BLACK | 2000 | Not Performed | Not Performed | Not Performed | + | | | | |
| BLACK | 4210 | Not Performed | Not Performed | Not Performed | + | 3350 | 730 | 0 | 0 |
| BLACK | 1790 | Not Performed | Not Performed | Not Performed | + | 1450 | 159 | 0 | 0 |
| BLACK | 19088 | 0 | 453 | 0 | + | 17200 | 225 | 425 | 0 |
| BLACK | 13074 | 0 | 0 | 0 | + | 10900 | 740 | 0 | 0 |
| BLACK | 271071 | 27281 | 0 | 0 | + | 223500 | 31500 | 0 | 0 |
| BLACK | 2767 | 363 | 41 | 152 | + | 2350 | 426 | 65 | 99 |
| BLACK | 24211 | 2082 | 0 | 9599 | + | 22100 | 1850 | 0 | 8875 |
| BLACK | 3875 | 299 | 2237 | 15.6 | + | 3670 | 245 | 2100 | 0 |
| BLACK | 23850 | 2563 | 1035 | 5031 | + | 19700 | 2375 | 990 | 4750 |
| BLONDE | 2539 | 289 | 36 | 0 | + | 2200 | 207 | 0 | 0 |
| BLONDE | 3478 | 226 | 0 | 0 | + | 3180 | 269 | 0 | 0 |
| BLACK | 299654 | 48105 | 17289 | 3398 | + | 260500 | 56700 | 16850 | 2840 |
| BLACK | 25943 | 2971 | 834 | 7814 | + | 23700 | 3590 | 935 | 7680 |
| GREY | 10330 | 746 | 285 | 2372 | + | 9950 | 880 | 250 | 2250 |
Using the methanolic extraction method, one out of the 32 previously positive samples produced negative results after storage at room temperature. The sample contained cocaine but at levels below the cutoff of the ELISA assay.
{12}
Page 1
i. Hair Treatment Effect on Negative and Positive Hair Samples
The effects of hairspray, hair gel, and bleaching on the screening assay were examined. Six negative samples of varying colors were selected and treated with hairspray, hair gel, and bleach prior to analysis. An untreated sample was also analyzed. Results were as follows:
| Hair Sample | Brown | Black #1 | Black #2 | White | Blond #1 | Blond #2 |
| --- | --- | --- | --- | --- | --- | --- |
| Untreated Absorbance | 3.16 | 3.142 | 3.175 | 3.146 | 3.208 | 3.226 |
| Hairspray Absorbance | 3.162 | 3.145 | 3.144 | 3.144 | 3.209 | 3.205 |
| Hair Gel Absorbance | 3.15 | 3.147 | 3.176 | 3.16 | 3.242 | 3.218 |
| Bleach Absorbance | 3.169 | 3.156 | 3.149 | 3.152 | 3.237 | 3.209 |
| Mean | 3.16025 | 3.1475 | 3.161 | 3.1505 | 3.224 | 3.2145 |
| Standard Deviation | 0.007848 | 0.006028 | 0.016872 | 0.007188 | 0.018019 | 0.009399 |
| % Coefficient of Variation | 0.248319 | 0.191508 | 0.533757 | 0.228153 | 0.558887 | 0.292381 |
Ten previously confirmed positive samples were treated with hairspray, hair gel, and bleach. An untreated sample was also analyzed. Results were as follows:
| No treatment | Hair Spray | | | Hair Gel | | | Bleach | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| B/B0* | B/B0 | Diff (%) | ELISA | B/B0 | Diff (%) | ELISA | B/B0 | Diff (%) | ELISA |
| 39.79 | 41.7 | 4.70 | + | 38.45 | -3.37 | + | 45.62 | 14.65 | + |
| 49.49 | 48 | -2.93 | + | 50.1 | 1.23 | + | 54.12 | 9.36 | - |
| 23.51 | 22.1 | -6.17 | + | 24.88 | 5.83 | + | 27.65 | 17.61 | + |
| 19.54 | 18.8 | -4.04 | + | 20.66 | 5.73 | + | 22.45 | 14.89 | + |
| 33.62 | 34 | 1.10 | + | 35.21 | 4.73 | + | 37.68 | 12.08 | + |
| 38.55 | 39.2 | 1.79 | + | 37.81 | -1.92 | + | 43.55 | 12.97 | + |
| 16.83 | 15.6 | -7.55 | + | 15.92 | -5.41 | + | 19.27 | 14.50 | + |
| 44.33 | 45.8 | 3.41 | + | 44.91 | 1.31 | + | 47.33 | 6.77 | + |
| 29.71 | 28.4 | -4.31 | + | 29.29 | -1.41 | + | 32.93 | 10.84 | + |
| 24.05 | 25.7 | 6.69 | + | 24.98 | 3.87 | + | 26.73 | 11.14 | + |
*B/B0 = absorbance of cutoff calibrator / absorbance of zero calibrator
{13}
Page 1
The sponsor noted a negative bias in the samples treated with bleach. In one case, a previously positive specimen tested negative after treatment with bleach.
2. Comparison studies:
a. Method comparison with predicate device:
A total of 157 samples (74 self-reported negative and 83 self-reported positive) were evaluated by the candidate device and by GC/MS and the predicate device.
Number of study sites: one
Type of study site: Manufacturer's facility
Operator description: Manufacturer's staff
Positive Agreement Study
This study enrolled 83 drug users who admitted using cocaine. The participants indicated frequency of usage ranging from daily use to once per month. The subjects ranged in age from 21 to 65 years old, and of the 83 subjects 17 were female and 66 were male. Hair color was distributed as follows: black – 56%, brown – 22%, gray – 20%, light brown – 1%, and blonde – 1%. Each subject provided a urine and a head hair sample.
Positive Agreement Study Results
| Number of Subjects | Self-Reported | Urine Screen Result* | Hair Screen Result – Aqueous Extraction | Hair Screen Result – Methanolic Extraction | Hair GC/MS Result** |
| --- | --- | --- | --- | --- | --- |
| 59 | + | + | + | + | + |
| 17 | + | - | + | + | + |
| 1 | + | - | - | - | + |
| 1 | + | + | - | + | + |
| 3 | + | - | - | - | - |
| 2 | + | - | - | + | + |
*300 ng/mL cutoff
**SAMHSA proposed cutoffs
Negative Agreement Study
This study enrolled 74 volunteers who self-reported as non cocaine users. The subjects ranged in age from 19 to 97 years old, and of the 74 subjects 33 were female and 41 were male. Hair color was distributed as follows: black – 45%, brown – 24%, blonde – 18%,
{14}
Page 15 of 15
gray – 5%, white – 5%, and red – 3%. Each subject provided a urine and a head hair sample.
## Negative Agreement Study Results
| Number of Subjects | Self-Reported | Urine Screen Result* | Hair Screen Result – Aqueous Extraction | Hair Screen Result – Methanolic Extraction | Hair GC/MS Result** |
| --- | --- | --- | --- | --- | --- |
| 70 | - | - | - | - | - |
| 3 | - | - | - | - | + |
| 1 | - | - | + | + | + |
*300 ng/mL cutoff
**SAMHSA proposed cutoffs
b. Matrix comparison:
Not applicable. The assay is intended for only one sample matrix.
3. Clinical studies:
a. Clinical sensitivity:
See comparison study above.
b. Clinical specificity:
See comparison study above.
c. Other clinical supportive data (when a and b are not applicable):
4. Clinical cut-off:
Not applicable.
5. Expected values/Reference range:
Cocaine should not be detectable in the hair of persons who have not used cocaine.
## N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10
## O. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.
Sort by:
Create Alert
Search Filters
Agent Token
Create a read-only bearer token for Claude, ChatGPT, or other agents that can call HTTP APIs.
Copy this now. It will not be shown again.
Connected apps
Apps you authorized through browser sign-in. Disconnecting revokes their access immediately.
Learn the FDA Browser
Two short videos show you everything — or skip straight to the written tutorial if you'd rather read. You can reopen this any time from the Tutorial button in the top bar.
Part 1 — Search, results, and everyday workflows 16 min
Part 2 — Embeddings: the galaxy map 3 min
1. Search: exact and fuzzy
Type a phrase like "coronary artery calcification" into the search box. You get two kinds of results. Exact results match the literal phrase — prefix searches work ("coronary artery calcificati") but suffix searches do not. Fuzzy results match on the meaning and intent of your phrase rather than the exact words, and are sorted by relevance score. Hover over the Exact or Fuzzy badge on any row to see exactly why it matched.
Use the checkboxes above the results to narrow: SaMD keeps only software-only devices, AI / ML keeps only devices with AI.
Exact vs. fuzzy search: what's the difference?
Exact matches on the literal phrase (prefix search works, suffix does not). Fuzzy matches on the meaning and intent of the phrase rather than the exact words. Hover over the badge on any row to see why it matched.
You search "coronary artery calcification" and want only software devices with AI. What two filters do you apply?
Narrow by SaMD (software-only devices), then narrow by AI/ML (devices with AI).
2. The results table
Scroll right in the results table. The intended use is extracted for you — no need to open the PDF. The device story gives a high-level snapshot of what the device does and how it's used. The AI Performance sub-table shows each output name, acceptance criteria, observed values, and development/test dataset descriptions — the same format Innolitics uses for regulatory strategy outputs, and the fastest high-level fingerprint of an AI device. It is AI-generated but has been very reliable in practice.
Where do you find a device's intended use without opening the PDF?
Scroll right in the search results table. The intended use column is extracted for you; no need to dig into the 510(k) summary PDF.
What does the AI Performance sub-table show, and why is it useful?
Output name, acceptance criteria, observed values, development dataset description, and test dataset description. It's the same format we use for regulatory strategy output and Fast 510(k) input, and the fastest high-level fingerprint of an AI device. AI-generated but reliable in practice.
3. Judging fuzzy relevance
Fuzzy results trail off in relevance as you scroll. Use three signals to decide how far down to go: the fuzzy badge explanations, the intended use column, and whether your target output (e.g., Cobb angle) still appears in the AI Performance sub-table. Once it stops appearing, you're past the relevant zone. A top hit with a low score (~0.4) and a stretched explanation is a hint the closest predicates are far away — the project may be headed for De Novo. Note the fuzzy search is a pattern match: it doesn't handle negation ("not") well, and hardware devices can appear — filter by SaMD/AI ML to cut them.
How do you judge how far down fuzzy search results to go?
Use the relevancy signals: the fuzzy badge explanations, the intended use column, and whether the target output (e.g., Cobb angle) still appears in the AI Performance sub-table. Once it stops appearing, results are trailing off in relevancy.
4. Device detail page: chat and citations
Click a device name to open its detail page: device facts on the left, a chat window on the right. Ask something like "Describe the training data". The answer carries little citation bubbles — click one to jump to the highlighted passage in the source PDF, so you can verify every AI answer against the document. There's also a Download PDF button for sharing.
How do you verify an AI chat answer on the device detail page?
Click the citation bubbles to jump to the relevant highlight in the source document.
Reading rule for every project: how many summaries do you read in full?
At least the three most relevant 510(k) or De Novo summaries, in full. After that, use targeted chat questions to confirm your memory quickly. The tool supports this professional habit — it doesn't replace it.
5. Side-by-side comparison
Select multiple rows in the results table (aim for under ~10), then open the PDF Viewer tab. Ask one question — it goes to all selected devices in parallel, each with citations. This is the fastest way to compare and contrast devices: training data, PCCP scope, how they handled adding new scanners, and so on.
What does the side-by-side PDF viewer mode do?
Select multiple devices, open the PDF viewer tab, and ask one question (e.g., "Describe the training data"). It queries all selected devices simultaneously with citations, so you can compare and contrast quickly.
6. Collections
With rows selected, go to the Collections tab and create a labeled collection (e.g., "Cobb Angle Project"). Reload that selection any time — before a client call, pull up the collection and ask questions across all of its devices at once.
How do you save a set of selected devices for later use?
Select the rows, go to the Collections tab, and create a labeled collection (e.g., "Cobb Angle Project"). You can reload the selection anytime and carry it into the PDF viewer and other tabs that support selections.
7. Product codes and the regulations tree
Click a product code in the results to jump to it in the regulations tree — identification text, sibling product codes, and devices you can open in a PDF viewer on the right. Click a regulation number to see its identification, special controls, and related product codes. You can also search by product code or regulation number at the top of the tree. Always read the special controls if any exist for your device — it broadens your search and sharpens pre-kickoff research.
What can you do from the regulations tree view?
Browse product codes and regulation numbers, read the identification text and special controls, browse sibling product codes, open device PDFs on the right, and search by product code or regulation number at the top of the tree.
8. Chart view
Click Show Chart and segment by regulation number (or product code) to see which regulations dominate your result set. Clicking a regulation takes you into the regulations tree. Great for spotting that most matches are, say, hardware laparoscopic devices — a cue to go back and filter.
How do you see which regulations dominate a search result set?
Click "Show Chart" and segment by Regulation Number. Clicking a regulation takes you to the regulations tree.
9. The predicate graph
Open the Predicates tab for a family-tree view of predicate relationships. Click a node to trace its parents and children; selections from search carry over pre-selected. Commonly predicated devices are worth reading — a lot of people predicated them for a reason. The visual lineage is also handy on client calls, e.g. to show how a predicate family evolved and justify why your predicate still holds.
In the predicate graph, why are commonly predicated devices worth reading?
A lot of people predicated them for a reason. Clicking a node traces parents and children, and selections from search carry over pre-selected.
10. Embeddings: the galaxy map
The Embeddings tab plots every matching document in a 2-D "galaxy map" where semantically similar devices cluster together. Hover or click clusters to explore, and let AI label the clusters for you. Embeddings beat product codes for grouping: two devices can carry different product codes (LLZ vs. QIH) yet do the same thing — the embedding captures the meaning of the intended use and device story. This is also exactly how retrieval-augmented generation (RAG) works under the hood, and it makes a great visual on client calls.
Try it yourself
Head to the search page and work through a few of these AI/ML fuzzy searches to build intuition: perivascular fat on CT · aortic valve calcification opportunistic screening on noncontrast CT · breast cancer prediction on digital pathology slides · autism detection · gestational age prediction · a hearing aid that can also detect a pulse · foundation model based analysis of ECG · large language models · penetration test. Watch how the relevance scores, intended use, and AI Performance tables tell you when results stop being meaningful.